Singapore-headquartered surgical robotics firm BIOBOT Surgical received S$10 million in fresh funding this month, disclosures with Singapore’s Accounting and Corporate Regulatory Authority (ACRA) show.
According to the filings, the round brought in a new investor, Temasek-established firm ClavystBio, which acquired 4,001,960 Series C preference shares for S$5 million.
Existing cornerstone shareholder ZIG Ventures Limited also doubled down in the round, taking up an additional 4,001,960 Series C preference shares at S$5 million.
In a shareholder resolution, the company described the fundraise led by ClavystBio as a Series C round, though it has yet to indicate whether this forms part of a larger tranche.
DealStreetAsia has reached out to BIOBOT Surgical and ClavystBio for comment.
The funding adds to BIOBOT’s institutional backing, with its cap table comprising a mix of individual and institutional investors.
Among the individual investors are oncologist Ang Peng Tiam and Lui Pao Chuen, a distinguished defence scientist.
On the institutional side, Astrid Hill Investment joins ZIG Ventures in the round. Other corporate investors include KUPA, PTSM Holdings, and Jia Yu Capital Pte. Ltd.
Founded in 2017, BIOBOT Surgical offers robotic-assisted biopsy and treatment for prostate cancer. It says it has completed more than 23,000 procedures and has secured five key regulatory clearances to date.
Its flagship robotic system, Mona Lisa, is used by surgeons across the US, China, Australia, Europe, and the Asia Pacific.
According to BIOBOT, prostate cancer remains one of the most pressing unmet needs in men’s health, ranking as the second-leading cause of cancer-related deaths among men globally. With 1.2 million cases diagnosed each year, the firm aims to position its technology to improve precision and outcomes in prostate cancer diagnosis and treatment.
